Biropepimut-S in phase IIb head and neck cancer trial
Biropepimut-S (GL-0817) is a highly engineered peptide immunomodulator currently in a double blind, placebo controlled clinical trial to prevent recurrence of high risk squamous cell cancer of the oral cavity. Patients with high risk SCCOC have a nearly 70% recurrence rate within 3 years despite surgery, chemoradiotherapy, and a clean CT scan.
Designed in response to previous challenges with clinical immunomodulator studies, biropepimut-S has a number of advanced features that enhance antigen presentation that are not available in any competitive product. These features and a carefully designed trial for a population with low initial tumor burden and high unmet medical need make this an important clinical trial for these patients.
Pfizer Advancing GL-2045
GL-2045 is a recombinant Fc fusion protein in clinical trial designed to mimic the effects of the pooled human blood product IVIG in treating autoimmune disease. IVIG sells about $8 billion annually and is approved for use clinically in numerous autoimmune diseases. Gliknik and Pfizer entered into a licensing agreement with Pfizer responsible for ongoing clinical development of the compound.
GL-2045 is from a class of compounds invented by Gliknik called stradomersTM, which present multiple immunoglobulin Fc simultaneously to Fc receptors and ligands as a means of modulating both Fc receptor-mediated activity and complement-mediated activity to treat autoimmunity.
Our Approach
At Gliknik, our mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders. Headquartered in downtown Baltimore, Gliknik’s expertise is in modulation of the immune system to fight disease.
Our perseverance and determination to make a difference in the lives of individuals with cancer and autoimmune disease is evidenced by the assembly of a talented team of scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.